Review: Platelet glycoprotein IIb/IIIa blockers for PCI or acute coronary syndromes reduce death and MI but increase bleeding

Bates, Eric R.
March 2002
ACP Journal Club;Mar/Apr2002, Vol. 136 Issue 2, p41
Academic Journal
Focuses on a study which investigated the effect of platelet glycoprotein IIb/IIIa blockers for percutaneous coronary intervention or acute coronary syndromes. Methodology of the study; Results; Comments on the outcome of the study.


Related Articles

  • Abatacept: A Viewpoint by Maxime Dougados. Dougados, Maxime // BioDrugs;2006, Vol. 20 Issue 1, p62 

    Eptifibatide (Integrilin) is a highly specific, reversible, intravenously administered glycoprotein IIb/IIIa receptor antagonist that acts at the final common step of the platelet aggregation pathway. Data from large clinical trials indicate that intravenous eptifibatide as adjunctive therapy to...

  • Glanzmann's thrombasthenia.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p956 

    An encyclopedia entry for "Glanzmann's thrombasthenia," which refers to a rare autosomal recessive abnormality of platelet glycoprotein IIb-IIIa that is characterized by easy bruising and epostaxis that may sometimes requires blood transfusions, is presented.

  • Short- and Long-Term Results of Abciximab Versus Aspirin in Conjunction with Thrombyolysis for Patients with Peripheral Occlusive Arterial Disease and Arterial Thrombosis. Schweizer, Johannes // Angiology;Nov2000, Vol. 51 Issue 11, p913 

    Evaluates the use of the platelet glycoprotein GP IIb/IIIa receptor antagonist abciximab versus aspirin in thrombolysis in patients with arterial thrombosis. Criteria for measuring primary efficacy; Reduction of the rates of rehospitalization; Decrease in the duration of lysis.

  • Inhibition of Human Platelet Function in Vivo with a Monoclonal Anti-body. Coller, Barry S.; Scudder, Lesley E.; Berger, Harvey J.; Iuliucci, John D. // Annals of Internal Medicine;10/15/88, Vol. 109 Issue 8, p635 

    Demonstrates that the abolition of platelet function mediated by the glycoprotein IIb/IIIa receptor can be achieved in human by in vivo infusion of 7E2-F(ab') [sub2] without immediate hemodynamic or hemorrhagic toxicity. Information on the F(ab') [sub2] fragment of a monoclonal antibody to the...

  • Platelet Glycoprotein IIb/IIIa Receptor Antagonists: Current Concepts and Future Directions. Ferguson, J.J.; Zaqqa, M. // Drugs;Dec1999, Vol. 58 Issue 6, p965 

    Platelets play a key role in the development of thrombosis. Glycoprotein (GP) IIb/IIIa antagonists are a new class of potent drugs that profoundly inhibit platelet function by blocking the key receptor involved in platelet aggregation. Several antiplatelet agents with varying characteristics...

  • Impact of Thrombophilic Genetic Factors on Pulmonary Embolism: Early Onset and Recurrent Incidences. Ivanov, Petar; Komsa-Penkova, Regina; Kovacheva, Katia; Ivanov, Yavor; Stoyanova, Angelina; Ivanov, Ivan; Pavlov, Plamen; Glogovska, Pavlina; Nojarov, Venzislav // Lung;Jan/Feb2008, Vol. 186 Issue 1, p27 

    The importance of genetic thrombophilic factors in the development of venous thromboembolism has been increasingly recognized. Factor V Leiden (FVL), prothrombin gene mutation G20210A (FII G20210), genetic variant C677T of the methylentetrahydrofolate reductase (MTHFR), as well as the...

  • Delayed Profound Thrombocytopenia Presenting 7 Days After Use of Abciximab (ReoPro). Sharma, Sanjiv; Bhambi, Brijesh; Nyitray, William; Sharma, Geetanjali; Shambaugh, Shawn; Antonescu, Adrian; Shukla, Pankaj; Denny, Eileen // Journal of Cardiovascular Pharmacology & Therapeutics;Jan2002, Vol. 7 Issue 1, p21 

    This article focuses on delayed profound thrombocytopenia presenting 7 days after use of abciximab. Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3 which binds to the platelet glycoprotein GP IIb-IIIa receptor and inhibits platelet aggregation. Acute profound...

  • New approaches to the management of AMI: Fibrinolysis plus GP llb/llla receptor blockade. Hilleman, Daniel E. // Formulary;Sep2000, Vol. 35 Issue 9, p738 

    Explains how acute myocardial infarction can be managed using fibrinolysis and platelet glycoprotein IIb/IIIa receptor blockade. Development of fibrinolytic agents; Thrombolytics; Advantages of bolus administration; Development of GP IIb/IIIa receptor inhibitors; Rationale for combination therapy.

  • Immunoexpression of Integrins in Ameloblastoma, Adenomatoid Odontogenic Tumor, and Human Tooth Germs. de Souza Andrade, Emanuel Sávio; da Costa Miguel, Marcia Cristina; de Almeida Freitas, Roseana; Pinto, Leão Pereira; de Souza, Lélia Batista // International Journal of Surgical Pathology;Jul2008, Vol. 16 Issue 3, p277 

    The expression of integrins α2β1, α5β1, and α5β1 in 30 ameloblastomas (20 solid and 10 unicystic tumors), 12 adenomatoid odontogenic tumors (AOTs), and 5 human tooth germs in different stages of odontogenesis was analyzed. The distribution, location, pattern, and intensity of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics